08.30 – 10.15
Amiodarone in patients with LV dysfunction: how safe is it?
G.L. Botto / Como, Italy
Ranalozine as a promising treatment option for AF, alone or in combination with
other AADs
A.J. Camm / London, UK
10.45 – 12.30
Increased mortality with dronedarone: is digoxin the cause?
A. Capucci/ Ancona, Italy
Dronedarone in the real world: how safe is it?
L. Friberg / Stockholm, Sweden
AF in patients with CAD: is dronedarone a good choice?
H.J.G.M. Crijns / Maastricht, The Netherlands
Dronedarone: which patient is most likely to benefit from it?
H.J.G.M. Crijns / Maastricht, The Netherlands
12.30 – 14.00
NOACs : pharmacological differences
A. Corsini / Milan, Italy
The clinical relevance of AMPLIFY programme
F. Dentali / Varese, Italy
Stroke prevention in non valvular atrial fibrillation: efficacy vs safety
G.L. Botto / Como, Italy
Challenging practical situations
A. Squizzato / Varese, Italy
14.00 – 15.45
After trans-catheter ablation
S. Themistoclakis / Venice-Mestre, Italy
16.15 – 17.25
New insight from ENGAGE
R.P. Giugliano/ Boston, USA
Real-life data from PREFER in AF Registry
R. De Caterina / Chieti, Italy
17.25 – 18.00
Have we changed the face of anticoagulation?
Speaker
S.J. Connolly/ Hamilton, Canada
18.00 – 19.30
Distinguished Scientist Golden Lionel Award
Lecture: History never looks like history when you are living through it
Sami Viskin
Distinguished Teacher Golden Lionel Award
Lecture: The Continuing Challenge of Catheter Ablation for Ventricular Tachycardia
Willian G. Stevenson